[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360754-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360754-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-immunity-cycle-based-molecular-subtypes-in-breast-cancer-predict-the-response-to-immune-checkpoint-inhibitors","Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors","","Cancer-immunity cycle (CIC) study frames anti-tumor immunity as sequential events from antigen release to T cell effector function, but a full patient-level CIC evaluation in breast cancer has been limited. A six-step CIC signature was built from primary tumors, used to compute CIC scores in a 752-patient cohort to define three CIC clusters, and then assessed for immune checkpoint inhibitor response in pan-cancer ICI-treated datasets. Multi-omic profiling including genomics, metabolomics, and single-cell RNA-seq characterizes cluster-specific immune, genomic, and metabolic patterns.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-immunity-cycle-based-molecular-subtypes-in-breast-cancer-predict-the-response-to-immune-checkpoint-inhibitors/360754/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-immunity-cycle-based-molecular-subtypes-in-breast-cancer-predict-the-response-to-immune-checkpoint-inhibitors/360754.png","ImageObject",300,407,{"name":42,"@type":43},"Ben ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of this study on the cancer-immunity cycle in breast cancer?","Question",{"text":63,"@type":64},"To comprehensively evaluate the cancer-immunity cycle in breast cancer patients and determine how CIC patterns relate to immune checkpoint inhibitor response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients grouped in the study?",{"text":68,"@type":64},"Patients were scored using a signature representing six CIC steps in the primary tumor, then classified into three CIC clusters based on the CIC activity.",{"name":70,"@type":61,"acceptedAnswer":71},"What multi-omic methods were used to characterize the CIC clusters?",{"text":72,"@type":64},"The clusters were further analyzed using genomics, metabolomics, and single-cell RNA sequencing to link immune features with genomic and metabolic patterns.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360754,1790198418,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Biol Med 2026. doi: 10.20892/j.issn.2095-3941.2025.0611  \nORIGINAL ARTICLE  \nCancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors  \nDi Shao 1,2*, Tianjian Yu 1,2*, Yi Xiao 1,2, Zhiming Shao 1,2  \n1 Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China  \n\n| ABSTRACT | Objective: The cancer-immunity cycle (CIC) outlines key steps of anti-tumor immunity from antigen release to T cell effector function. A comprehensive evaluation of the CIC in patients with breast cancer is lacking, which limits the accurate assessment of immune status and selection of patients suitable for immune checkpoint inhibitor (ICI) therapy.\u003Cbr>Methods: A signature that describes the six steps of the CIC in the primary tumor was constructed. This signature was used to calculate a CIC score in our previously published breast cancer cohort (n = 752) and classify patients into 3 distinct CIC clusters. The predictive value of the ICI response was validated in pan-cancer ICI-treated cohorts. Clusters with distinct characteristics were further identified through multi-omic analyses, including genomics, metabolomics, and single-cell RNA sequencing.\u003Cbr>Results: Breast cancer patients were classified into three CIC clusters: cluster 1 [C1](immune-cold); cluster 2 [C2] (antigen presentation-deficient); and cluster 3 [C3](immune-hot) . C3 showed abundant immune infiltration that correlated with a better ICI response. In addition to reduced immune infiltration, C1 patients exhibited macrophage phenotypic conversion. The tumor microenvironment ofC2 was marked by elevated regulatory T cells and dysfunctional dendritic cells. Genomic analysis ofC2 showed a high tumor mutational burden with frequent HLA loss of heterozygosity. C1 was enriched in lipid metabolism pathways and C3 in glycolysis features. PSAT1, a serine-related gene, was identified as a key metabolic regulator in C2, suggesting a role in influencing immunoregulatory molecules.\u003Cbr>Conclusions: This study provided a novel framework for classifying tumors based on the CIC characteristics, revealing distinct biological and clinical profiles and suggesting broad clinical significance. |\n| --- | --- |\n| KEYWORDS | Cancer-immunity cycle; tumor immunity; immune checkpoint inhibitor; breast cancer; PSAT1 |\n\nIntroduction  \nImmune checkpoint inhibitor (ICI) treatment, which targets the reversal of immunosuppression in CD8+ T cells, has significant efficacy in breast cancer patients1,2. ICI combined with chemotherapy improves survival in metastatic and operable patients with triple-negative breast cancer (TNBC) compared to chemotherapy alone3-5. Recent studies have also confirmed an improved pathologic complete response (pCR) in hormone receptor (HR)-positive patients who received adjuvant  \n*These authors contributed equally to this work. Correspondence to: Yi Xiao and Zhiming Shao  \n[E-mail: yixiao11@fudan.edu.cn](E-mail: yixiao11@fudan.edu.cn) and [zhiming_shao@fudan.edu.cn](zhiming_shao@fudan.edu.cn)  \nORCID ID: [https://orcid.org/0000-0003-2946-9921](https://orcid.org/0000-0003-2946-9921) and [https://orcid](https://orcid).  \norg/0000-0002-4503-148X  \nReceived October 18, 2025; accepted December 23, 2025;  \npublished online March 5, 2026. Available [at www.cancerbiomed.org](at www.cancerbiomed.org)  \n©2026 The Authors. Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4 .0)  \nICI treatment6. However, while ICIs improve the efficacy of neoadjuvant treatment, approximately 40% of TNBC patients still do not achieve a pCR, which exceeds 70% in HR-positive patients6,7 . How to leverage a deeper immunologic understanding of breast cancer patient heterogeneity to improve ICI treatment remains a challenge.  \nThe cancer-immunity cycle (CIC) was conceptualized based on a progressively deeper und","cbCaioj0Z3X0d2RX","https://ap.wps.com/l/cbCaioj0Z3X0d2RX","pdf",14615333,21,"English","# Abstract\n## Introduction\n## Study flowchart\n## Part 1: Evaluating CIC status\n## Part 2: CIC step-based clustering\n## Part 3: Prognostic value of CIC clusters\n## Part 4: Multi-omics analysis of CIC clusters","[{\"question\":\"What is the main objective of this study on the cancer-immunity cycle in breast cancer?\",\"answer\":\"To comprehensively evaluate the cancer-immunity cycle in breast cancer patients and determine how CIC patterns relate to immune checkpoint inhibitor response.\"},{\"question\":\"How were patients grouped in the study?\",\"answer\":\"Patients were scored using a signature representing six CIC steps in the primary tumor, then classified into three CIC clusters based on the CIC activity.\"},{\"question\":\"What multi-omic methods were used to characterize the CIC clusters?\",\"answer\":\"The clusters were further analyzed using genomics, metabolomics, and single-cell RNA sequencing to link immune features with genomic and metabolic patterns.\"}]","Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors | PDF",1790141429,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6db16da54cfe39b9145c604145be229.webp",983,1287,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8b7045cbefaebcc7df92fa66f3f6b38.webp",982,1286,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/437c53518902aaf31d1f424721b3ef12.webp",981,1284,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6dd0ef97074f8139dabcf39f5642c90d.webp",980,1283]